Aliskiren, a direct renin inhibitor (DRI), has therapeutic effects in patients with hypertension and associated complications, but its potential mechanism in diabetic nephropathy is lacking. The effects of aliskiren in Streptozotocin (STZ)-induced renal complication in diabetic rats were investigated. Aliskiren treatment for eight weeks at the dose of 10 mg/kg/day, via osmotic mini-pump, induced improvement in blood glucose levels, systolic blood pressure (BP) and serum creatinine. Improvement of insulin resistance by aliskiren was confirmed by increased glucose translocation in liver and muscle and hence insulin levels. The treated group also showed improvement in glomerulosclerosis and tubulointerstitial injury. Aliskiren treatment also improved albumin levels in plasma, suppressed profibrotic and proinflammatory cytokine synthesis viz TNF-α and TGF-β and angiogenesis by a decrease in VEGF. In addition, the level of total proteins and GFR via cystatin c and beta-2microglobulin along with adiponectin and erythropoietin were also improved. These results suggest that the beneficial organ protective effect of aliskiren is mediated by improvement in insulin resistance as well as a direct anti-fibrotic effect in the target organ in STZ-induced diabetic rats with a slight effect on blood pressure. Aliskiren may be a useful therapeutic agent in the treatment of type 2 diabetes and diabetic nephropathy.
Introduction
Dysregulation of the renin-angiotensin-aldosterone system (RAAS) has an important role in the development of target organ damage in diabetes mellitus. [1] [2] [3] Therefore, drugs targeting RAAS suppression have been most widely used for preventing or delaying target organ damage. 1 Most RAAS blockers, however, are not completely effective in preventing or reversing diabetic complications, which could be due to the stimulation of renin that results from the negative feedback loop associated with decreased angiotensin II activation. Thus, direct renin inhibition appears to be more rational to create a complete and effective blockade of RAAS activity without a rebound increase in plasma renin activity (PRA). 4, 5 Aliskiren is the first drug of a new class of agents known as renin inhibitors, which directly inhibit renin in order to decrease PRA. 6 Unlike previous renin inhibitors, aliskiren has better oral bioavailability and an extended half-life. 7 The most recent reports for aliskiren treatment revealed effective organ protection related to an anti-hypertensive effect. [8] [9] [10] [11] Previous studies showed protective renal and cardiac benefits of aliskiren treatment by monotherapy or combination therapy with other RAAS blockades in both human and animal studies. But there is a lack of evidence on the effects of aliskiren on insulin resistance and renal variables along with a decline in the extent of apoptosis in the kidney in delaying the progression of target organ injury in a type 2 diabetic animal model. Recent hypertension trials have reported a lower incidence of diabetes mellitus among patients treated with RAAS inhibitor when compared with other classes of anti-hypertensive medications. 12, 13 Although most of the patients from those studies presented with hypertension or congestive heart failure, a 22% relative risk reduction for new-onset diabetes mellitus was demonstrated in a meta-analysis of randomized controlled trials. 14 In spite of these firm clinical data, the anti-diabetic mechanism of RAAS blockade ameliorating the diabetic complications is yet to be resolved. Multiple mechanisms such as improving insulin signaling pathways, insulin secretion by pancreatic beta cells and modulation of adipocytokines in the adipose tissues [15] [16] [17] have been suggested. In the present study, we investigated mechanisms behind the beneficial effect of aliskiren on diabetic microvascular renal complications in type 2 diabetic rats. Since RAAS plays an important role in insulin resistance, we also examined the effect of aliskiren on insulin resistance and glucose translocation in liver and skeletal muscle.
Materials and methods

Materials
Aliskiren (10 mg/kg/day subcutaneously (s.c.) via osmotic drug delivery) procured from Novartis, R & D Base, Switzerland, Basel, Rat Albumin ELISA by (ICL Cat E-25L Lot #14), Ultra sensitive Rat Insulin ELISA Kit (by Crystal Chem. Inc Catalog # 90060), Rat Erythropoietin ELISA Kit (Cusabiotech Co. Catalog no. CSB-E07323r), Rat beta-2 microglobulin (BMG, Cusabiotech Co. Catalog no. CSB-E11298r), Rat Cystatin C (Cys-C) ELISA Kit (Cusabiotech Co. Catalog no. CSB-E08385r), Rat transforming growth factor β1 (TGF-β1) ELISA kit (Cusabiotech Co. Catalog no. CSB-E04727r), Rat TNF-α ELISA Kit (Raybio Cat#ELR-TNFalpha-001), Human/Mouse/Rat Adiponectin Enzyme Immunoassay Kit (Raybio Cat#EIA-ACRP-1), Rat VEGF ELISA Kit (Raybio Cat#ELR-VEGF-001).
Animals
Healthy albino rats of Wistar strain were kept for breeding. To induce non-insulin dependent diabetes mellitus (NIDDM), Streptozotocin (STZ) (Sigma Chemicals, WA, USA) (90 mg/kg/day) was administered intraperitoneally (i.p.) to a group of two-day-old pups. Another group of pups received only saline. The pups were weaned for 21 days, and six weeks after the injection of STZ, the animals were checked for fasting plasma glucose level (FPG); levels ≥ 160 mg/dl were considered as diabetic. Pups that received saline were considered as control animals, after which they were grouped so that the blood glucose levels were uniform among the groups. All rats were housed under conventional conditions with controlled temperature, humidity and light (12-hour light-dark cycle) and were provided with a standard commercial diet and water (ad libitum). All experimental procedures were conducted according to the Institutional Animal Ethical Committee (protocol no. DIPSAR / IAEC / 2009/01) and Committee for the Purpose of Control and Supervision of Experiments on Animals (India) (CPCSEA) guidelines.
Eight-week chronic daily dosing study
After six weeks, the animals were assigned to receive vehicle or aliskiren (10 mg/kg/day s.c.) for eight weeks using an osmotic mini-pump. In the morning after final drug administration, blood samples were collected under fasting conditions and body weight was measured; and the kidney was isolated and fixed in phosphate-buffered 10% formalin solution to prepare a paraffin section.
Glucose transporter (GLUT)2 expressions in liver and GLUT4 expressions in soleus muscle
For determination of GLUT2 protein expressions in liver and GLUT4 protein expressions in skeletal muscle, each sample prepared was mixed with 1% sodium dodecyl sulfate and 50 mM dithiothreitol, and the mixture was subjected to electrophoresis with 10% polyacrylamide gel. The separated proteins on the gel were electrotransferred to a polyvinylidene difluoride membrane. After blocking with a 5% skim milk solution including 0.05% poly (oxyethylene) sorbitan monolaurate (Tween 20) overnight at 4°C, the membrane was reacted with anti-GLUT-2 antibody (Abcam, Cambridge, UK) and anti-GLUT-4 antibody (Abcam) for two hours. Subsequently, it was incubated with horseradish peroxidase conjugated IgG (diluted 1:2000) (Jackson Immunoresearch Laboratories, PA, USA) for two hours at room temperature. The blots were detected with chemiluminescence reagents (Western Blot). 18 
Measurement of hemodynamic parameters in normal rats
Systolic, diastolic and mean blood pressure (BP) were measured by using a tail cuff apparatus (Kent Scientific, CT, USA).
Measurement of renal function and biochemical parameters
Biochemical markers were measured, including blood glucose, plasma insulin, serum albumin, total plasma proteins; glomerular proteins viz β-2 microglobulin, serum cystatin c and serum creatinine, for the estimation of glomerular filtration rate (GFR), transforming growth factor (TGF-β 1 ) and other molecular markers, specifically adiponectin and erythropoietin, and inflammatory markers tumor necrosis factor alpha (TNF-α), nitric oxide (NO) and vascular endothelial growth factor (VEGF).
Histopathology
Kidney sections were stained with either periodic acid-Schiff's reagent or Masson's modified trichrome to assess glomerulosclerosis and collagenous tubulointerstitial matrix, respectively. 10 
Glomerulosclerotic index
In 4μm kidney sections stained with periodic acid-Schiff's reagent, 150 glomeruli from each animal were examined in a masked protocol. The extent of sclerosis in each glomerulus was subjectively graded on a scale of 0 to 4, 19 with the following grades: grade 0 normal, grade 1 sclerotic area <25% (minimal), grade 2 sclerotic area 25-50% (moderate), grade 3 sclerotic area 50-75% (moderate to severe) and grade 4 sclerotic area 75-100% (severe). A glomerulosclerotic index was then calculated using the formula:
Where GSI is the glomerulosclerotic index, Fi is the percentage of glomeruli in the rat with a given score (i).
Quantitation of matrix deposition
The accumulation of matrix within the tubulointerstitial was assessed on Masson's trichrome-stained sections. An area of blue on a trichrome-stained section was selected for its color range, and the proportional area of tissue with this range of color was then semi-quantified and graded by similar method for GSI and tubulointerstitial index (TIMI).
DNA fragmentation assay
For detection and localization of apoptosis in the pancreas, we used the technique of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) (Apo-BrdU-IHC TM In Situ DNA Fragmentation Assay Kit, Biovison, CA, USA). Briefly, sections were deparaffinized, hydrated and digested with proteinase K (20 μg/ ml), and then biotinylated dUTP was added to the 3′ end of DNA fragments by incubating sections in 0.05 mol/l Tris-HCl buffer (pH 7.6) with 0.03 U/μl TdT and 0.04 nmol/μl biotin-11-dUTP at 37°C for one hour. The sections were rinsed in phosphate-buffered saline (PBS).
Endogenous peroxidase was blocked with 0.3% H 2 O 2 in distilled H 2 O. The sections were rinsed with PBS and covered with 2% blocking solution in 0.1 mol/l sodium maleate to reduce background staining. The sections were then incubated with avidin-peroxidase complexes in PBS (1:50) for 30 minutes and rinsed with PBS (3×5 minutes). Peroxidase activity was visualized with 3,3′-diaminobenzidine until the brown product was clearly visible. The sections were then counterstained with methyl green. The positive apoptotic cells were the cells with brown nucleus. 20 
Statistical analysis
All data are expressed as the mean ±S.E.M. The differences in all parameters were analyzed by a one-way analysis of variance (ANOVA) followed by a Dunnett's Multiple Comparison Test using sigma plot. 11 A change was considered statistically significant if P<0.05.
Results
Effect of aliskiren on body weight and blood glucose
Before the treatment, there were no significant differences of baseline body weight of the rats (Table 1 ). In the aliskiren (10 mg/kg)-treated rats, a significant increase in body weight was noted (224.2±4.1g, P<0.001), as compared with diabetic groups (198.3±3.1g) after eight weeks of study (Table 1) .
Before treatment, there was significantly higher FPG (p < 0.001) in all groups when compared with normal ( Table 1) . After eight weeks, groups treated with aliskiren showed a significant reduction of blood glucose versus the diabetic group (p < 0.01) ( Table 1 ).
Effect of aliskiren on liver GLUT2 and muscle GLUT4 expression
In diabetic rats, GLUT2 expression in liver and GLUT4 expression in soleus muscle was reduced; whereas aliskirentreated rats showed improvement in both GLUT2 and GLUT4 expressions ( Figure 1 ). 
Biochemical markers
Plasma insulin. Aliskiren at the dose 10 mg/kg significantly increased plasma insulin (p<0.01) levels in the treated diabetic rats as compared with the diabetic groups after eight weeks ( Table 2) .
Total proteins and albumin in plasma
Total proteins levels were found to increase significantly in plasma of the aliskiren-treated diabetic rats (p<0.001), whereas the increase in plasma level of albumin was not statistically significant (Table 2 ).
Hemodynamic parameters
Aliskiren at the depressor dose of 10 mg/kg reduced the systolic blood pressure by 13.4% ( Figure 2 ). The relationship between blood pressure and urinary protein excretion during treatment with aliskiren was further examined by correlation analysis. There was no correlation between blood pressure and serum protein in rats treated with a depressor-dose of aliskiren (r = −0.194). In contrast, serum albumin levels were strongly correlated with blood pressure in rats that were treated with depressor-dose aliskiren (r = 0.92) (data not published).
Glomerular filtration rate, renal proteins and inflammatory markers
Serum creatinine. Diabetic control rats had elevated serum creatinine (normal: 1.79±0.21 mg/dl; diabetic: 3.59±0.27 mg/dl), which was significantly reduced with aliskiren (P<0.01) after eight weeks of chronic dosing ( Table 2) .
Serum cystatinc
Serum cystatin c has been increased in the diabetic rats. Treatment of the STZ-induced diabetic nephropathy rats with aliskiren significantly decreased the serum cystatin c levels (P<0.05) ( Table 2) .
Beta-2 microglobulin
The treatment with aliskiren caused a significant decrease in the serum beta-2 microglobulin concentrations (p< 0.01) in comparison with the diabetic control group ( Table 2) .
The area under the receiver operating characteristic (ROC) curve for cystatin c was observed as 0.98 and that of creatinine was 0.67, indicating better diagnostic efficiency values for cystatin c than creatinine (Figure 3 ).
TNF-alpha
This can be further supported by the significant difference in the mean values of TNF-α observed in plasma between the normal control and diabetic group (P<0.01) ( Table 2) . After the eight-week treatment with 10 mg/kg dose of aliskiren, the levels of TNF-α significantly decreased when compared with the levels in the diabetic rats (P<0.01) ( Table 2 ).
NO
NO levels were significantly increased in diabetic groups (p<0.01). On treatment with aliskiren, NO levels were found to decrease in comparison with the diabetic group (p< 0.05) ( Table 2 ).
Growth factor
Transforming Growth Factor-β1 (TGF-β1). TGF-β1, a key participant in the development of kidney sclerosis, significantly differs in the diabetic and normal control groups (P<0.001) ( Table 2 ). The concentration of TGF-β1 was decreased significantly (P<0.05) when compared with the diabetic group after eight weeks of treatment with aliskiren ( Table 2) .
VEGF
VEGF is a critical component in the tissue growth and organ repair processes of angiogenesis and vasculogenesis. VEGF was significantly lower in the control groups than in the diabetic group (P<0.001). The aliskiren treatment showed lowering of VEGF levels in diabetic rats but data was not found to be statistically significant ( Table 2 ).
Molecular markers
Adiponectin. Adiponectin was measured as a surrogate marker for inflammation and was significantly lower in the diabetic group than in the normal control group (P<0.01).
On treatment with aliskiren, adiponectin levels were increased but the augmentation was not found to be statistically significant ( Table 2 ). 
Erythropoietin
The erythropoietin concentrations were found to increase significantly (P<0.05) after treatment with aliskiren for eight weeks when compared with the diabetic group (Table 2) .
Histopathology
In control rats, the kidney cortex appeared normal with only some glomeruli displaying thickened glomerular basement membranes (GBM) (Figure 4 ). In contrast, in diabetic control rats most glomeruli exhibited thickened GBM, capillary occlusion and mesangial expansion. In addition, many cortical tubules were vacuolated (Figure 4) . In diabetic rats treated with aliskiren, glomerular pathology was improved (Figure 4 ).
GSI
Diabetes was associated with an increase in GSI compared to diabetic control rats. GSI was lower in diabetic rats treated with aliskiren ( Figure 4 ).
Quantitation of matrix deposition
In the tubule-interstitium of kidney cortex or medulla, increased collagen and inflammatory cells were observed in diabetic rats compared to normal rats. Compared to diabetic control rats, interstitial fibrosis was lower in diabetic rats treated with aliskiren monotherapy (Figure 4 ).
DNA fragmentation
There was an evident increase in the DNA fragmentation in the diabetic kidney compared to the normal kidney ( Figure 4 ), whereas the kidney treated with aliskiren showed a clear decrease in the extent of DNA fragmentation (Figure 4 ).
Discussion
The direct inhibition of renin is a logical target for pharmacologic suppression of the RAAS because renin-mediated cleavage of angiotensinogen to form angiotensin I is a ratelimiting first step in the RAAS pathway. The neonatal-STZ Wistar model is a well characterized model of type 2 diabetes. Neonatal-STZ rats develop persistent diabetes rapidly after six weeks of age and show diabetes-like symptoms such as lack of insulin release in response to glucose, glucose intolerance, raised glycosylated hemoglobin and depletion of pancreatic insulin store. [21] [22] [23] [24] Further, when rendered diabetic with STZ, they develop renal damage considered analogous to that seen in human diabetic nephropathy. 25 At the same time, it has been said that diabetes induced by STZ injection significantly downregulates the protein expression of ACE-2 and Ang-(1-7) mas R, which eventually causes renal hypertrophy, tissue injury and apoptosis via the upregulation of phosphorylation of ERK1/2, p38 MAPK and JNK protein expression. 26 The blood pressure-lowering efficacy of aliskiren in hypertensive patients is also well known and authenticated by various clinical trials. 8, 9, 27 Pilz et al. also demonstrated a protective effect of aliskiren for both heart and kidney injuries in double transgenic rats for human renin and angiotensinogen genes. 10 However, in a recent Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) clinical study, aliskirenin combined with losartan had a significant anti-proteinuric effect that was independent of its blood pressure-lowering effect in patients with hypertension and diabetic nephropathy. 28, 29 Kelly et al. illustrated that aliskiren had a similar efficacy to the angiotensin-converting enzyme (ACE) inhibitor in reducing urinary albumin and glomerulosclerosis in diabetic transgenic (mRen-2)27 rats. 11 Together, these results suggest a beneficial effect of renin inhibition in hypertensive and diabetic renal disease.
In the present study, we demonstrated that aliskiren treatment significantly improved insulin resistance and renal variables in STZ-induced diabetes without much effect on blood pressure. Aliskiren treatment also showed organ-protective effects such as improvement of functional and structural changes in the kidney. We also provided evidence that aliskiren could inhibit renin-mediated activation of profibrotic and angiogenic cytokine markers through an angiotensin-dependent mechanism.
The dosage of aliskiren used in the present investigation was selected on the basis of previous studies. 11 In pursuant to that, the diabetic rats in the present study experienced approximately an 81% decrease in plasma/ serum pancreatic insulin content, which was significantly improved with aliskiren treatment. At the same time, aliskiren treatment significantly reduced blood glucose and increased body weight as compared to diabetic rats.
The glucotransporter isoforms GLUT2 and GLUT4 play central roles in the complex pathways mediating whole body glucose disposal, in which dysregulation of their controlling mechanism can result in the pathophysiologic states associated with diabetes. 30 Aliskiren-treated diabetic rats showed improved liver and muscle glucotransporter expression levels qualitatively. These results qualify the improved insulin sensitivity of aliskiren. The findings are in accordance with a recent study that demonstrates that renin inhibition attenuates insulin resistance and improves systemic insulin sensitivity in transgenic Ren2 rats that over-express renin. 30, 31 Thus, a possible link between renin activation and insulin resistance is suggested.
Furthermore, proteinuria, insulin resistance and formation of reactive oxygen species (ROS) are also associated with loss of adiponectin level in diabetic rats. STZ-induced diabetic rats showed almost an 87% decrease in adiponectin levels as compared with normal rats, which was ameliorated on treatment with aliskiren. Adiponectin can improve both glucose metabolism and insulin resistance via the AMP-activated protein kinase (AMPK) signaling pathway, both in liver and muscle, thereby lowering the blood glucose concentrations in vivo. 32, 33 Studies have shown that phosphorylation of AMPK-α (thr172) is decreased in diabetic rats. The decreased plasma adiponectin levels may partly explain the decreased phosphorylation of AMPK-α (Thr172) in diabetic rats. Phosphorylation of AMPK increases glucose transport by stimulating the translocation of GLUT4. 26 The improvement of adiponectin levels in the diabetic treated rats can further be confirmed by the significant increase in body weight of the animals on aliskiren treatment, though the increase in adiponectin levels was not significant. Hence, we propose from our findings that RAAS blockade increased adiponectin concentrations with a consequent improvement in insulin sensitivity and secretion. 34 This was in accordance with the clinical study to assess plasma adiponectin as an independent predictor of type 2 diabetes especially in Asian Indians. 35 Indeed, adiponectin has also been shown to accumulate in injured vessel walls and dose-dependently inhibit TNF α-induced cell adhesion in human aortic endothelial cells. 36 Furthermore, TNF-alpha mRNA and protein levels were found to be increased in renal tissue from diabetic rats, which has been directly related to principal alterations of diabetic nephropathy as well as in cellular apoptosis and necrosis. 37 The present study confirms the significant reduction in levels of TNF-alpha in serum after eight weeks of chronic dosing with aliskiren when compared with the diabetic control group, thereby inhibiting apoptosis.
Moreover, chronic hyperadiponectinemia had been shown to alleviate the progression of proteinuria in earlystage diabetic nephropathy. The mechanism whereby adiponectin decreases proteinuria has been shown to involve an increase in nephrin expression, and demonstrates an improvement of the endothelial dysfunction because of decreases in ET-1 and PAI-1 in the renal cortex. 38 Hence, we also tried to explore the changes in renal function on treatment with the depressor dose of aliskiren. Increased urinary albumin excretion (UAE) is the hallmark of diabetic nephropathy. Studies indicate that albuminuria is a major renal and cardiovascular risk factor in patients with diabetes, and that the degree of albuminuria reduction under treatment is critical in terms of long-term clinical outcome. [39] [40] [41] Interventions that have attenuated the progression of diabetic nephropathy have been associated with a reduction in urinary protein excretion, 42 and thus renoprotective therapy should aim to achieve the maximal antialbuminuric effect. 43 However, a recent study proposed that in 20 diabetic patients with macroalbuminuria, large quantities of protein fragments, not routinely measured clinically, were present. 44 Also, lower serum albumin concentration imposes a greater increase in relative risk of mortality among populations as serum values of albumin are not readily affected by minor variations by the body's natural mechanism of maintaining homeostasis in albumin metabolism. 45 Albumin, being a major source of sulphydryl groups, 46 may be important in the activation of a systemic inflammatory response. Hence, we chose serum/plasma albumin as an important marker for identification of progression of renal damage. In our study, treatment of STZinduced diabetic rats with aliskiren prevented the development of albuminuria that was seen in vehicletreated diabetic controls, as the plasma albumin levels were found to increase after eight weeks of treatment with aliskiren, despite negligible differences in blood pressure in treated diabetic rats. Further, decrease in plasma proteins may also elicit pro-inflammatory and pro-fibrotic effects that directly contribute to chronic tubulo-interstitial damage. 47 Consequently, an increase in protein and albumin levels was achieved with obvious drug effect on glucose metabolism and insulin levels. However, the increase in either was at least partially independent of the decrease in blood pressure as the reduction is desirable in diabetic nephropathy, a microvascular complication, where patients are normally observed to be hypertensive. This BP independent effect was verified by examining the correlation between individual values of BP and serum total protein. The variance of serum albumin in this group is due to the effects of aliskiren on systolic BP, suggesting that intrarenal effects may also play an important role along with systemic blood pressure in manipulating the renal variables with this drug. This finding is consistent with those of earlier published preclinical and clinical studies. 48, 49 Moreover, it is still not confirmed whether these beneficial actions of aliskiren are due to its antihypertensive effect or renin inhibition. Nonetheless, it has also been reported that renin inhibition with aliskiren attenuated renal vascular resistance and significantly reduced BP in diabetic patients, which was observed in our study also. As monotherapy, aliskiren has been shown to be equally effective as an ACE inhibitor or ARB in lowering BP, but not more effective. 8, [50] [51] [52] Several explanations can be proposed, 53 but the simplest is that the renin-angiotensin system is only one of the many regulatory pathways contributing to hypertension. The modest BP reduction with aliskiren monotherapy most likely reflects compensation. Regardless of the precise explanation, aliskiren does not eliminate the need for multi-drug regimens to control most cases of hypertension, nor is it expected to be a magic bullet for resistant hypertension and renal complications in diabetic patients.
Additionally, the aliskiren treatment was found to decrease the NO levels in the study undertaken, which could be because of an increase in the renal expression of the p47phox component of NAD (P) H oxidase and eNOS, thereby decreasing the indices of systemic and renal oxidative/ nitrosative stress as proposed by Sonta et al. in 2005. 54 Besides, kidney also has a finite capacity to regulate intraglomerular pressure so that some transmission of systemic pressure to the glomerular tuft still occurs. These effects are magnified by the local synthesis of angiotensin II, which by preferentially constricting the efferent arteriole, raises intra-glomerular pressure. Further, it induces the expression of fibrotic growth factors, namely TGF-β1 and VEGF via MAPK p42/p44, thereby upregulating molecules like fibronectin, collagen-1 and plasminogen-activator inhibitor-1 (PAI-1), [55] [56] [57] leading to glomerulosclerosis. [58] [59] [60] In the present study, aliskiren reduced glomerulosclerosis significantly, which is further supported by significant reduction of TGF-β1 and VEGF. VEGF in glomeruli has been associated with glomerular hypertrophy and increased production of alpha3 (IV) collagen, which is an integral component of the GBM, thereby leading to sclerosis. The findings were consistent with a two-fold increase of glomerular VEGF mRNA in transgenic (mRen-2)27 rats. 61 Aliskiren treatment in the present investigation also attenuated tubulointerstitial fibrosis, another important predictor of renal dysfunction, 11 which has been explained by the prevention of desmin expression, which preserves podocytes and protects against interstitial fibrosis. 62 In addition, anemia has been associated with an accelerated decline in renal function in some of the patient groups. Decreased tissue oxygen delivery caused by anemia stimulates the RAAS and contributes to renal vasoconstriction. These factors can further exacerbate proteinuria, which may worsen renal function. In patients with type 2 diabetes, anemia has been shown to be an independent risk factor for progression of renal disease. 63 The improvement of erythopoeitin levels with aliskiren treatment shows a wide range of effects produced by the aliskiren treatment in delaying the progression to renal complications.
Further, to substantiate the renal variables, measuring GFR is widely accepted as the best overall index of kidney function. In clinical practice, an approximation of GFR is often obtained from plasma/urine creatinine concentration alone, albeit with limited accuracy. 64 Pure and reliable urinary samples are very challenging to obtain from experimental animals, especially from small rodents. 65 Moreover, serum creatinine is particularly insensitive for identifying chronic kidney disease in its early to middle stages and in certain patient groups (e.g. children, females, elderly). 66 It is also considered relatively specific but not very sensitive since its levels significantly increase only when more than 50% of the GFR is reduced. Measurement of cystatin c or beta2-microglobulin (B2M) concentrations has been found to be advantageous over serum creatinine concentration for the detection of an impaired GFR. 67 Cystatin c and B2M are low-molecular weight endogenous proteins freely filtered by the glomerulus and proximal tubule, respectively. 68 It is already shown that serum cystatin c levels rise earlier and more rapidly than those of serum creatinine as GFR decreases, reflecting greater sensitivity and hence diagnostic accuracy 69 (related to GFR measured as 51Cr-EDTA clearance 70 ) of cystatin c as a predictor of GFR in type 2 diabetic patients. Also, serum cystatin c level is correlated strongly with 24-hour creatinine clearance (r = 0.832, p <0.001). 71 ROC plot analysis in our study confirm these findings of cystatin c being a sensitive diagnostic marker for renal impairment with an area under the curve (AUC; 95% confidence interval (CI)) of 0.98 being superior to that of serum creatinine (0.67, 95% CI). Further, beta-2 microglobulin, another endogenous filtration marker, by virtue of its retention due to renal function failure, is deposited in tissues and aggregated into fibrils, and hence become glycosylated. 72 However, B2M is unstable in acid and degrades in infected alkaline urine during the time when the urine is held in the bladder; hence its absence cannot be relied on to exclude the presence of a tubular proteinuria. 73 Therefore, we performed the analysis of the filtration markers in serum. Also their serum concentrations are less dependent on extra renal factors than serum creatinine. In nephrotic syndrome, the increased excretion of low molecular weight plasma protein is probably explained by accompanying tubular malfunction, but in renal failure the overwhelming reabsorptive capacity in the less-affected nephrons is the major factor. Virtually, studies have shown that patients excreting increased quantities of low molecular weight proteins were also excreting increased amounts of albumin, so an increased albumin excretion does not necessarily indicate glomerular disease. In the present study conducted, it was clear that monotherapy with aliskiren improved the creatinine clearance, which is evident from the significant decrease in serum creatinine values. At the same time, serum levels of cystatin c and BMG were significantly decreased when compared with diabetic rats after chronic administration of aliskiren. These findings were consistent with the earlier study done by Byung et al. in 2007. 74 Further, even mild renal impairment is strongly associated with increased mortality in patients; 75 the ROC analysis validates the sensitivity and specificity of cystatin c measurement to assess the substantially reduced GFR effectively, thereby reducing the progression of morbidity and mortality by aliskiren treatment and hence justifying its efficacy in renal complication of diabetes over creatinine-based measures.
Conclusion
The present study authenticates the use of direct renin inhibition (DRI) as a renoprotective agent, in addition to its utility as an antihypertensive. The ability to provide a more complete inhibition of RAAS by overcoming the expected limitations of angiotensin II receptor blockers and ACE inhibitors, and thereby preventing possible renal-damaging direct effects of renin including apoptosis of the kidney, make DRIs appealing to nephrologists. Nevertheless, the study cannot rule out the use of a combination of drugs to provide an effective blockade of the renin angiotensin system, thereby providing more efficient renoprotection by inhibiting angiotensin-dependent and independent pathways with slight changes in BP. The elevation of prorenin as a compensatory mechanism in patients with diabetic nephropathy further needs special attention and could make it unsafe in the long run. However, better glucose translocation in liver and muscle along with renal variables testifies to the beneficial use of aliskiren in diabetic complications.
